19 completed, 5 terminated, 2 unknown. 13 Phase 1, 10 Phase 2, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 10, Terminated 2, Unknown 1 |
| Phase 2 | 10 | Completed 6, Terminated 3, Unknown 1 |
| Phase 3 | 5 | Completed 4, Terminated 1 |
Follow brivanib: new trials by email Literature Review of brivanib trials Research Report on brivanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer niraparib combined with brivanib, niraparib combined with toripalimab - Cervical Cancer | Phase 2 | Unknown | Chongqing University Cancer Hospital | 38 | 2020-05-08 | 2021-05-21 |
| MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Zai Lab (Shanghai) Co., Ltd. | 89 | 2020-04-20 | 2024-07-23 |
| A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer niraparib, Brivanib - Ovarian Cancer | Phase 1 | Unknown | Hunan Cancer Hospital | 24 | 2019-01-14 | 2019-03-29 |
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC Brivanib 800 mg, QD, Brivanib 400 mg, BID - Hepatocellular Carcinoma (HCC) | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 90 | 2017-05-17 | 2019-09-04 |
| Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) Brivanib - Hepatocellular Carcinoma | Phase 1 | Completed | Bristol-Myers Squibb | 17 | 2012-03-01 | 2014-07-08 |
| Brivanib Metastatic Renal Cell Carcinoma Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250 - Renal Cell Carcinoma | Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 10 | 2011-11-01 | 2021-04-13 |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF Brivanib, Irinotecan - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2011-08-01 | 2020-09-03 |
| Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Brivanib Alaninate, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2011-04-04 | 2019-03-20 |
| Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment Brivanib, Placebo - Carcinoma, Hepatocellular | Phase 3 | Terminated | Bristol-Myers Squibb | 87 | 2010-05-01 | 2015-10-12 |
| Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) 5-FU, Leucovorin, Irinotecan - Gastro-Intestinal Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 49 | 2010-02-01 | 2014-09-16 |
| Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC Brivanib, Brivanib Placebo, TACE Therapy - Hepatocellular Carcinoma | Phase 3 | Completed | Bristol-Myers Squibb | 734 | 2009-07-20 | 2019-12-02 |
| Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Brivanib Alaninate, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 45 | 2009-07-06 | 2017-12-06 |
| First Line Hepato Cellular Carcinoma (HCC) Brivanib, Placebo, Sorafenib - Hepato Cellular Carcinoma (HCC) | Phase 3 | Completed | Bristol-Myers Squibb | 1714 | 2009-05-01 | 2016-10-17 |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers Capecitabine, Doxorubicin, Ixabepilone - Advanced Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 111 | 2009-03-01 | 2015-07-07 |
| Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment Brivanib, Placebo, Best Supportive Care - Liver Cancer | Phase 3 | Completed | Bristol-Myers Squibb | 587 | 2009-02-17 | 2019-10-09 |
| Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types brivanib, Placebo - Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma | Phase 2 | Completed | Bristol-Myers Squibb | 597 | 2008-06-01 | 2015-10-09 |
| Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer cetuximab, brivanib alaninate - Colorectal Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 750 | 2008-05-12 | 2023-08-04 |
| Phase I/II Combination With Irinotecan- Erbitux Cetuximab, Irinotecan, Brivanib - Metastatic Colorectal Cancer (MCRC) | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 38 | 2008-05-01 | 2015-11-04 |
| A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Brivanib - Solid Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 13 | 2007-10-01 | 2011-01-25 |
| A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) Brivanib - Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 4 | 2007-09-01 | 2009-01-22 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Hepatocellular (6) · Colorectal Neoplasms (4) · Neoplasms (3) · Liver Neoplasms (2) · Neoplasm Metastasis (2) · Uterine Cervical Neoplasms (2) · Acrocephalosyndactylia (1) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Ovarian Neoplasms (1) · Pyloric Stenosis, Hypertrophic (1) · Rectal Neoplasms (1)
Bristol-Myers Squibb (17) · Gynecologic Oncology Group (2) · Zai Lab (Shanghai) Co., Ltd. (2) · Abramson Cancer Center at Penn Medicine (1) · Chongqing University Cancer Hospital (1) · Hunan Cancer Hospital (1) · M.D. Anderson Cancer Center (1) · NCIC Clinical Trials Group (1)
United States (18) · Canada (9) · China (9) · France (6) · South Korea (6) · Argentina (5) · Italy (5) · Spain (5) · Taiwan (5) · Hong Kong (4) · Japan (4) · Belgium (3) · Germany (3) · United Kingdom (3) · Australia (2)
John K Chan (1) · Lillian L. Siu, MD, FRCPC (1) · Matthew Powell (1) · Michael Overman, MD (1) · Qi Zhou, Ph.D. (1) · Stephen Keefe, MD (1) · ZhengGang Ren, PhD (1)
PMID 16110319, PMID 21131369, PMID 21349999, PMID 23552472, PMID 23690424, PMID 23719718, PMID 23980084, PMID 23980090, PMID 24474817, PMID 25326159, PMID 25592089, PMID 25651787, PMID 28131794, PMID 28728751, PMID 29365411, PMID 30466310, PMID 34052255, PMID 37185961, PMID 40215447
U10CA027469 (2), U10CA180868 (2), 2009 (1)